Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
Фаза 3
Завершено
NCT03353350
| Заболевание | Type 2 Diabetes Mellitus |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | Hanmi Pharmaceutical Company Limited |
|---|
| Статус | Завершено |
|---|
| Участники | 406 участн. |
|---|
| Вмешательство | efpeglenatide (SAR439977) |
|---|
| Дата начала | 5.12.2017 |
|---|
| Дата завершения | 29.01.2020 |
|---|
| Публикация результатов | 18.01.2022 |
|---|
Кратко
Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with T2DM (Type 2 Diabetes Mellitus) inadequately controlled with diet and exercise. Secondary Objectives: * To demonstrate the superiority of once-weekly injection of efpeglenatide in comparison to placebo on glycemic control * To demonstrate the superiority of once-weekly injection of efpeglenatide in comparison to placebo on body weight * To evaluate the safety of once-weekly injection of efpeglenatide
Change in Glycated Hemoglobin (HbA1c) (%)
Baseline to Week 30 · HbA1c (%)
| Placebo | -0.46 ± 1.16 HbA1c (%) |
|---|
| Efpeglenatide 2 mg | -1.14 ± 0.96 HbA1c (%) |
|---|
| Efpeglenatide 4 mg | -1.48 ± 1.01 HbA1c (%) |
|---|
| Efpeglenatide 6 mg | -1.59 ± 1.04 HbA1c (%) |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.